Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BMP Sunstone to acquire Shengda Pharmaceutical
Terms of the acquisition are not yet finalized, as completion is subject to a number of conditions including finalization of due diligence and definitive documentation. The company intends
Terms of the acquisition are not yet finalized, as completion is subject to a number of conditions including finalization of due diligence and definitive documentation. The company intends
The Named Patient Access Program (NPAP) is a compassionate use drug supply program administered by the Health Sciences Authority (HSA) of Singapore and Drug Control Authority (DCA) of
This study sponsored by PDL BioPharma and conducted at the following Multiple Myeloma Research Consortium (MMRC) Member Institutions: the University of Michigan, Dana-Farber Cancer Institute, University of Chicago,
Dr Mantzoros is an associate professor of medicine at Harvard Medical School and an associate professor in epidemiology at the Harvard School of Public Health. Dr Mantzoros obtained
In a controlled study conducted at MPI Research of Mattawan, Minnesota, Proellex showed no potential for tumor induction as compared to controls in the gross findings. Proellex or
Irribow is a serotonin 5-HT3 receptor antagonist discovered by Astellas. According to the company, Irribow improves abnormal defaecation associated with the acceleration of intestinal transit by inhibiting 5-HT3
The goals of the trial at the Hadassah Medical Center in Ein Kerem, in which ten lupus patients took part, were to demonstrate the safety and efficacy of
Under the terms of the agreement, Amgen will receive a minority equity interest in Gamida Cell in addition to royalty payments from future sales of StemEx for hematological
Mr Schnittker succeeds Brian Lenz, who resigned to accept a CFO position with a biotechnology company and will stay on with VioQuest until August 14, 2008 to assist
According to the company, ColonSentry is the world’s first blood-based test that assesses a patient’s current risk of having colorectal cancer, identifying those in the asymptomatic general population